急性心肌梗死患者流感疫苗接种的最佳时机——来自IAMI试验的发现
IAMI试验将2571例急性心肌梗死患者随机分配为流感疫苗组或生理盐水安慰剂组,在2016年10月1日至2020年3月1日期间于8个国家30个中心开展。此项事后探索性亚研究比较早期季节接种(n=1188)与晚期季节接种(n=1344)患者的结局,主要终点为12个月全因死亡、心肌梗死或支架血栓形成的复合终点。早期接种组疫苗vs安慰剂的主要复合终点发生率为6.0% vs 8.4%(HR 0.69;95%CI 0.45-1.07),晚期接种组为4.7% vs 6.2%(HR 0.74;95%CI 0.47-1.18),交互作用P=0.848。结论认为证据不足以确定早期与晚期接种的效力差异,但无论接种时机如何,强烈推荐所有心血管疾病患者接种流感疫苗。
要点
- 早期接种组主要复合终点:疫苗6.0% vs 安慰剂8.4%(HR 0.69;95%CI 0.45-1.07)。
- 晚期接种组主要复合终点:疫苗4.7% vs 安慰剂6.2%(HR 0.74;95%CI 0.47-1.18)。
- 早期接种组全因死亡HR 0.50(95%CI 0.29-0.86),晚期接种组HR 0.75(95%CI 0.40-1.40),交互作用P=0.335。
核心结论
- 试验证据不足以确定早期与晚期接种的效力差异,但无论接种时机如何,强烈推荐所有心血管疾病患者接种流感疫苗。
研究设计与样本
- IAMI试验为随机对照试验,将2571例急性心肌梗死患者随机分配为流感疫苗组或生理盐水安慰剂组,于2016年10月1日至2020年3月1日在8个国家30个中心开展。
- 本分析为事后探索性亚研究,比较早期季节接种(n=1188)与晚期季节接种(n=1344)患者的结局。
主要发现
- 早期接种组主要复合终点:疫苗组36例(6.0%)vs 安慰剂组49例(8.4%),HR 0.69(95%CI 0.45-1.07)。
- 晚期接种组主要复合终点:疫苗组31例(4.7%)vs 安慰剂组42例(6.2%),HR 0.74(95%CI 0.47-1.18)。
- 主要复合终点的交互作用P=0.848(HR尺度,1年)。
- 全因死亡:早期接种组HR 0.50(95%CI 0.29-0.86),晚期接种组HR 0.75(95%CI 0.40-1.40),交互作用P=0.335。
- 心血管死亡等关键次要终点结果相似,疫苗接种对不良心血管事件的效力无统计学显著时机差异。
临床怎么用
- 作者强烈推荐所有心血管疾病患者接种流感疫苗,无论接种时机如何。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza vaccination reduces the risk of adverse cardiovascular events.The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344).The primary endpoint wasthe composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. Thecumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion,there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccinationbut regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.
引用
- Akhtar Z, Götberg M, Erlinge D, et al. Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial. Vaccine. 2023. PMID: 37925315. doi:10.1016/j.vaccine.2023.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。